Rajesh Bandekar

2.5k total citations
48 papers, 1.3k citations indexed

About

Rajesh Bandekar is a scholar working on Oncology, Surgery and Hematology. According to data from OpenAlex, Rajesh Bandekar has authored 48 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 13 papers in Surgery and 13 papers in Hematology. Recurrent topics in Rajesh Bandekar's work include Multiple Myeloma Research and Treatments (13 papers), Nausea and vomiting management (9 papers) and Prostate Cancer Treatment and Research (7 papers). Rajesh Bandekar is often cited by papers focused on Multiple Myeloma Research and Treatments (13 papers), Nausea and vomiting management (9 papers) and Prostate Cancer Treatment and Research (7 papers). Rajesh Bandekar collaborates with scholars based in United States, Netherlands and Belgium. Rajesh Bandekar's co-authors include A. Mark Fendrick, Ming Qi, James M. Scheiman, Michael E. Chernew, Amid I. Ismaïl, Helgi van de Velde, John F. Randolph, G. R. Hudes, Mary Crutchfield and M. Anthony Schork and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.

In The Last Decade

Rajesh Bandekar

46 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rajesh Bandekar United States	19	405	377	273	262	221	48	1.3k
Ewald Wöll Austria	19	535 1.3×	476 1.3×	170 0.6×	272 1.0×	109 0.5×	56	1.3k
Verena De Angelis Italy	19	582 1.4×	402 1.1×	516 1.9×	270 1.0×	77 0.3×	58	1.5k
Yanyan Wang China	20	242 0.6×	180 0.5×	297 1.1×	446 1.7×	211 1.0×	75	1.5k
Christoph Schwarz Austria	22	275 0.7×	283 0.8×	519 1.9×	477 1.8×	82 0.4×	66	1.7k
Norihiro Sato Japan	15	505 1.2×	302 0.8×	659 2.4×	360 1.4×	103 0.5×	44	1.9k
Patrick Starlinger Austria	26	529 1.3×	183 0.5×	511 1.9×	334 1.3×	84 0.4×	129	1.7k
Sébastien Viatte United Kingdom	19	161 0.4×	282 0.7×	233 0.9×	307 1.2×	250 1.1×	54	1.7k
Hironori Hayashi Japan	22	442 1.1×	235 0.6×	341 1.2×	305 1.2×	53 0.2×	97	1.2k
Masayoshi Okumi Japan	26	441 1.1×	456 1.2×	792 2.9×	371 1.4×	134 0.6×	186	2.1k
Masaharu Nishikido Japan	18	266 0.7×	403 1.1×	326 1.2×	337 1.3×	53 0.2×	58	1.0k

Countries citing papers authored by Rajesh Bandekar

Since Specialization

Citations

This map shows the geographic impact of Rajesh Bandekar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rajesh Bandekar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rajesh Bandekar more than expected).

Fields of papers citing papers by Rajesh Bandekar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rajesh Bandekar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rajesh Bandekar. The network helps show where Rajesh Bandekar may publish in the future.

Co-authorship network of co-authors of Rajesh Bandekar

This figure shows the co-authorship network connecting the top 25 collaborators of Rajesh Bandekar. A scholar is included among the top collaborators of Rajesh Bandekar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rajesh Bandekar. Rajesh Bandekar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bahleda, Rastilav, Elena Lorenzo, Ramón Yarza, et al.. (2025). 1566P Phase I study of intratumoral administration of JNJ-87704916, an oncolytic virus, as monotherapy and in combination with cetrelimab in advanced solid tumors. Annals of Oncology. 36. S871–S871.

Parasrampuria, Dolly A., Rajesh Bandekar, & Thomas A. Puchalski. (2020). Scientific diligence for oncology drugs: a pharmacology, translational medicine and clinical perspective. Drug Discovery Today. 25(10). 1855–1864.

Rathkopf, Dana E., Emmanuel S. Antonarakis, Neal D. Shore, et al.. (2017). Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone. Clinical Cancer Research. 23(14). 3544–3551. 64 indexed citations

Brighton, Timothy, Simon J. Harrison, David Ghez, et al.. (2017). A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab (Anti IL-6 Monoclonal Antibody) in Patients with High-Risk Smoldering Multiple Myeloma. Blood. 130. 3155–3155. 5 indexed citations

Smith, Matthew R., Emmanuel S. Antonarakis, Charles J. Ryan, et al.. (2016). Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. European Urology. 70(6). 963–970. 100 indexed citations

Bandekar, Rajesh, Ming Qi, Helgi van de Velde, et al.. (2015). Dose selection of siltuximab for multicentric Castleman’s disease. Cancer Chemotherapy and Pharmacology. 75(5). 1037–1045. 10 indexed citations

Hofmeister, Craig C., Hartmut Goldschmidt, Ming Qi, et al.. (2015). Centaurus (JNJ5467414SMM2001): A Randomized Phase II Trial to Evaluate Three Daratumumab (DARA) Dose Schedules in Smoldering Multiple Myeloma (SMM). Clinical Lymphoma Myeloma & Leukemia. 15. e175–e175. 1 indexed citations

Orlowski, Robert Z., Liana Gercheva, Cathy Williams, et al.. (2014). A phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. American Journal of Hematology. 90(1). 42–49. 115 indexed citations

Rathkopf, Dana E., Emmanuel S. Antonarakis, Neal D. Shore, et al.. (2014). ARN-509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without prior abiraterone acetate (AA) treatment.. Journal of Clinical Oncology. 32(15_suppl). 5026–5026. 5 indexed citations

10.

Thomas, Sheeba K., А. Н. Суворов, Lucien Noens, et al.. (2013). Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma. Cancer Chemotherapy and Pharmacology. 73(1). 35–42. 11 indexed citations

11.

Roila, Fausto, Janusz Rolski, Rodryg Ramlau, et al.. (2009). Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting. Annals of Oncology. 20(11). 1867–1873. 27 indexed citations

12.

Herrstedt, Jørn, Wichit Arpornwirat, István Albert, et al.. (2008). Safety and efficacy of the novel antiemetic neurokinin-1 (NK-1) receptor antagonist, casopitant, in women with breast cancer (BC) receiving moderately emetogenic chemotherapy (MEC) – subgroup analysis from a randomized, double-blind, placebo-controlled phase II trial. European Journal of Cancer Supplements. 6(7). 196–197. 2 indexed citations

13.

Rolski, Janusz, Rodryg Ramlau, Mircea Dediu, et al.. (2006). Randomized phase II trial of the neurokinin-1 receptor antagonist (NK-1 RA) casopitant mesylate with ondansetron (ond)/dexamethasone (dex) for chemotherapy-induced nausea/vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC). Journal of Clinical Oncology. 24(18_suppl). 8513–8513. 12 indexed citations

14.

Hoberman, Alejandro, Ron Dagan, Eugene Leibovitz, et al.. (2005). Large Dosage Amoxicillin/Clavulanate, Compared With Azithromycin, for the Treatment of Bacterial Acute Otitis Media in Children. The Pediatric Infectious Disease Journal. 24(6). 525–532. 50 indexed citations

15.

Bandekar, Rajesh & Daya K. Nagar. (2003). Matrix variate Cauchy distribution. Statistics. 37(6). 537–550. 1 indexed citations

16.

Ellis, Charles N., Kristin L. Reiter, Rajesh Bandekar, & A. Mark Fendrick. (2002). Cost-effectiveness comparison of therapy for psoriasis with a methotrexate-based regimen versus a rotation regimen of modified cyclosporine and methotrexate. Journal of the American Academy of Dermatology. 46(2). 242–250. 24 indexed citations

17.

Rich, Melissa, A. Mark Fendrick, Michael E. Chernew, Rajesh Bandekar, & James M. Scheiman. (2000). Cost-effectiveness of step-up vs. Step-down therapy for symptomatic gerd: An international perspective. Gastroenterology. 118(4). A216–A217. 2 indexed citations

18.

Nallamothu, Brahmajee K., A. Mark Fendrick, Melvyn Rubenfire, et al.. (2000). Potential Clinical and Economic Effects of Homocyst(e)ine Lowering. Archives of Internal Medicine. 160(22). 3406–3406. 20 indexed citations

19.

Ismaïl, Amid I. & Rajesh Bandekar. (1999). Fluoride supplements and fluorosis: a meta‐analysis. Community Dentistry And Oral Epidemiology. 27(1). 48–56. 48 indexed citations

20.

Pienta, Kenneth J., Bruce G. Redman, Rajesh Bandekar, et al.. (1997). A phase ii trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology. 50(3). 401–407. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact